BeiGene announced that clinical results and updates from its diverse immuno-oncology portfolio will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2021 being held December 8-11, 2021. To bring forth potential new treatment options and uncover further insights into checkpoint inhibition in solid tumors and hematological malignancies, BeiGene is evaluating tislelizumab, a potentially differentiated anti-PD-1 antibody, in a broad clinical program, including 13 Phase 3 trials and four pivotal Phase 2 trials, and in collaboration with Novartis. At ESMO IO, results from an interim analysis of the randomized, double-blind, Phase 3 RATIONALE 309 trial (NCT03924986) evaluating tislelizumab in combination with chemotherapy in recurrent or metastatic nasopharyngeal cancer (RM-NPC) will be presented in a Proffered Paper. These results supported the regulatory submission in China for NPC. Combination strategy is considered key to overcoming primary and acquired resistance to anti-PD-1 therapy and expanding clinical benefit of immunotherapy to more patients. BeiGene is investigating the potential of novel tislelizumab combinations to drive stronger and more sustained tumor responses and impede tumor immune escape. At ESMO IO, results from two cohorts of a Phase 1b trial (NCT03666143) evaluating tislelizumab in combination with the oral, spectrum-selective kinase inhibitor sitravatinib in metastatic melanoma and platinum-resistant ovarian cancer will be presented. BeiGene is developing sitravatinib in collaboration with Mirati Therapeutics Inc. Additionally, BeiGene will share details on the design of the Phase 3 AdvanTIG-301 trial (NCT04866017) evaluating its investigational Fc-competent anti-TIGIT-antibody ociperlimab in combination with tislelizumab and concurrent chemoradiotherapy (eCRT) as a first-line treatment for patients with locally advanced, unresectable non-small cell lung cancer.